Artiva is deeply committed to making effective and safe cell therapies broadly accessible to patients with autoimmune disease.
Are available treatments for systemic lupus erythematosus (SLE) and/or lupus nephritis (LN) not working for you?
Artiva Biotherapeutics is a clinical-stage biotechnology company focused on developing and advancing natural killer (NK) cell-based therapies. With a mission to bring effective, safe, and accessible treatments to patients, Artiva is deeply committed to transforming the care of those living with devastating autoimmune diseases and cancers. By harnessing the power of NK cells, the company aims to overcome current limitations in cell therapy and make these innovative treatments broadly available to patients in need.
Find out if you are eligible to participate in a clinical study
A clinical trial or clinical study looks at better ways to prevent, diagnose, and treat disease. The main purpose of this study is to learn if AlloNK (AB-101), an investigational NK cell therapy, is safe for people with SLE or LN, and if AlloNK can help improve their condition. This study will also look at how well the treatment is tolerated and how the body responds to AlloNK.
This study is testing a combination of AlloNK and another treatment called a B-cell depleting monoclonal antibody (mAb). B-cells are a type of immune cell that can play a role in causing SLE. The goal of combining these treatments is to lower the number of B-cells in your body. This gives the immune system a chance to reset, which may help stop your immune system from attacking your own body. This study will help to see if AlloNK could lead to clinical improvement in SLE symptoms for people who have not responded well to other treatments.
What is the purpose of this clinical study?
A clinical trial or clinical study looks at better ways to prevent, diagnose, and treat disease.
AlloNK® for Lupus Nephritis - FAQ
Common Questions
AlloNK® is designed to boost the immune system by using NK cells that are donated by health volunteers. It’s meant to work with other treatments and can be given outside the hospital, in places like clinics or doctor’s offices.
The study will take around 24 months. You will have 26 office visits over the 2 years.
Clinical research depends on volunteers like you to participate to help improve treatments and advance medical knowledge. Participants play a key role in finding safe and effective therapies. Participating is a personal choice. You may decide not to participate, or you may leave the study at any time.
Your participation in this clinical study helps us learn more about systemic lupus erythematosus (SLE) and/or lupus nephritis (LN) and, hopefully, find a new and accessible treatment.
If you participate in this clinical study, you will get:
-
Access to trying an investigative treatment that
may work for you -
Extra tests and monitoring from study doctors
-
While we try to lower risks as much as possible, some side effects may occur. But the clinical study team will watch you closely, adding another layer of care.
The Sponsor will cover all costs for the AlloNK study treatment, as well as any study-related visits, tests, hospitalizations, and procedures done specifically for the study. The Sponsor will cover the costs of travel, hotels, and meals associated with participation in the study.
If you are an adult with systemic lupus erythematosus (SLE) and/or lupus nephritis (LN) and other treatments have not worked well, this could be the right study for you. Complete the form below to learn more about AlloNK® for SLE and/or LN.
I am Interested in the clinical study!
Please complete the form and we will contact you with more information.
